How Cannabinoids Regulate Nausea, Vomiting, and Gut Pain | Research

The takeaway

A review of cannabinoid receptors throughout the GI tract found strong evidence for their role in regulating nausea and vomiting, but limited and unsupportive clinical data for visceral pain conditions like IBS.

Read this if you have GI symptoms and are considering cannabis or interested in how cannabinoids affect gut function.

Animal models support visceral pain relief; clinical IBS data does not

What the researchers found

This review mapped cannabinoid receptors (CB1, CB2, and potentially GPR55) throughout the gastrointestinal tract and examined their roles in food intake, nausea, gastric secretion, motility, visceral sensation, inflammation, and cell proliferation.

The strongest evidence supported cannabinoid involvement in regulating nausea and vomiting, where the endocannabinoid system has provided new mechanistic insights. For visceral pain, animal models consistently showed that cannabinoids reduced sensitivity, but clinical data in IBS patients was scarce and did not support benefit.

Emerging drug targets, particularly FAAH and MAGL inhibitors, showed promise in animal studies but lacked human validation. The review highlighted that compounds acting on these targets could avoid the psychoactive side effects of direct cannabinoid receptor agonists.

Why it matters

The GI tract contains a dense network of cannabinoid receptors, making it a logical therapeutic target. But this review revealed a gap between promising preclinical findings and disappointing clinical results, particularly for pain conditions.

The numbers in context

Three cannabinoid receptor types identified in the GI tract (CB1, CB2, GPR55); FAAH and MAGL inhibitors identified as novel drug targets; IBS clinical data described as scarce and not supportive

How the study worked

Narrative review of basic science and clinical literature on cannabinoid receptors and endocannabinoid signaling in the gastrointestinal tract.

What this study cannot tell us

Narrative review without systematic methodology. Clinical data for GI applications was limited at the time. Animal model results may not translate to humans. Did not address cannabinoid hyperemesis syndrome in detail.

How to read the evidence

Comprehensive narrative review of basic science and clinical evidence, limited by sparse human data for GI pain applications.

When this study was published

Published in 2015. Research on cannabinoids for GI conditions has continued, though clinical breakthroughs remain elusive.

The bigger picture

The future of cannabinoid-based GI therapy may lie not in traditional THC-like drugs but in compounds that boost endocannabinoid levels (FAAH/MAGL inhibitors) or act only on peripheral receptors, avoiding central nervous system side effects.

Questions still open

Will peripherally-acting cannabinoid drugs prove effective for IBS and other functional GI disorders? Can FAAH/MAGL inhibitors deliver clinical benefits without psychoactive side effects? How does chronic cannabis use affect GI cannabinoid receptor function?

Common questions

Can cannabis help with IBS?

As of this 2015 review, animal studies showed cannabinoids could reduce visceral pain sensitivity, but clinical data in IBS patients was scarce and did not support benefit. The disconnect between animal and human results remains an active area of research.

Why does cannabis affect the gut?

The gastrointestinal tract contains cannabinoid receptors (CB1, CB2, and GPR55) that regulate motility, secretion, inflammation, and pain sensation. Cannabis compounds activate these receptors, producing effects throughout the digestive system.

Read the original research

The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.

Current gastroenterology reports, 17(2), 429

View on PubMed ↗Publisher’s paper ↗

Citation

Malik, Zubair; Baik, Daniel; Schey, Ron. (2015). The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.. Current gastroenterology reports, 17(2), 429. https://doi.org/10.1007/s11894-015-0429-1